Bugworks, which is headquartered in the U.S. with subsidiaries in India and Australia, specializes in the development of antibiotics that could address the growing crisis of antimicrobial resistance.
Asking whether China is the future of the biotech industry might seem counterintuitive, considering the current biotech geopolitical context. If you haven’t followed this series of events, a ...
This week on the podcast, we have a conversation with Fran Gregory, vice president of Emerging Therapies at Cardinal Health. The discussion covers the company’s role in healthcare, biosimilars, the ...